These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

230 related articles for article (PubMed ID: 34053791)

  • 41. Updated Characterization of Outbreak Response Strategies for 2019-2029: Impacts of Using a Novel Type 2 Oral Poliovirus Vaccine Strain.
    Kalkowska DA; Pallansch MA; Wilkinson A; Bandyopadhyay AS; Konopka-Anstadt JL; Burns CC; Oberste MS; Wassilak SGF; Badizadegan K; Thompson KM
    Risk Anal; 2021 Feb; 41(2):329-348. PubMed ID: 33174263
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Outbreaks of Circulating Vaccine-Derived Poliovirus in the World Health Organization Western Pacific Region, 2000-2021.
    Kitamura K; Shimizu H
    Jpn J Infect Dis; 2022 Sep; 75(5):431-444. PubMed ID: 36047174
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Detection of vaccine-derived poliovirus circulation by environmental surveillance in the absence of clinical cases.
    Odoom JK; Obodai E; Boateng G; Diamenu S; Attiku K; Avevor P; Duker E; Boahene B; Eshun M; Gberbie E; Opare JKL
    Hum Vaccin Immunother; 2021 Jul; 17(7):2117-2124. PubMed ID: 33517832
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Environmental Surveillance Complements Case-Based Surveillance of Acute Flaccid Paralysis in Polio Endgame Strategy 2019-2023.
    Chen P; Liu Y; Wang H; Liu G; Lin X; Zhang W; Ji F; Xu Q; Tao Z; Xu A
    Appl Environ Microbiol; 2020 Jul; 86(15):. PubMed ID: 32444474
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Vaccine-associated paralytic poliomyelitis and other diseases with acute flaccid paralysis syndrome in Belarus.
    Samoilovich EO; Feldman EV; Yermalovich MA; Protas II; Titov LP
    Cent Eur J Public Health; 2003 Dec; 11(4):213-8. PubMed ID: 14768785
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Impact of Supplementary Immunization Activities using Novel Oral Polio Vaccine Type 2 during a Large outbreak of Circulating Vaccine-Derived Poliovirus in Nigeria.
    Voorman A; Lyons H; Shuaib F; Adamu US; Korir C; Erbeto T; Bandyopadhyay AS; Okiror S
    J Infect Dis; 2024 Mar; 229(3):805-812. PubMed ID: 37357964
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Genetic Characterization of Novel Oral Polio Vaccine Type 2 Viruses During Initial Use Phase Under Emergency Use Listing - Worldwide, March-October 2021.
    Martin J; Burns CC; Jorba J; Shulman LM; Macadam A; Klapsa D; Majumdar M; Bullows J; Frolov A; Mate R; Bujaki E; Castro CJ; Bullard K; Konz J; Hawes K; Gauld J; Blake IM; Mercer LD; Kurji F; Voorman A; Diop OM; Oberste MS; Modlin J; Macklin G; Eisenhawer M; Bandyopadhyay AS; Zipursky S
    MMWR Morb Mortal Wkly Rep; 2022 Jun; 71(24):786-790. PubMed ID: 35709073
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Update on Vaccine-Derived Poliovirus Outbreaks - Worldwide, January 2021-December 2022.
    Bigouette JP; Henderson E; Traoré MA; Wassilak SGF; Jorba J; Mahoney F; Bolu O; Diop OM; Burns CC
    MMWR Morb Mortal Wkly Rep; 2023 Apr; 72(14):366-371. PubMed ID: 37022974
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Strengthening acute flaccid paralysis surveillance post Ebola virus disease outbreak 2015 - 2017: the Liberia experience.
    Clarke A; Blidi N; Dahn B; Agbo C; Tuopileyi R; Rude MJ; Williams GS; Seid M; Gasasira A; Wambai Z; Skrip L; Nagbe T; Nyenswah T; Chukwudi JO; Johnson T; Talisuna A; Yahaya AA; Rajatonirina S; Fall IS
    Pan Afr Med J; 2019; 33(Suppl 2):2. PubMed ID: 31402963
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Emergence of Vaccine-Derived Polioviruses during Ebola Virus Disease Outbreak, Guinea, 2014-2015.
    Fernandez-Garcia MD; Majumdar M; Kebe O; Fall AD; Kone M; Kande M; Dabo M; Sylla MS; Sompare D; Howard W; Faye O; Martin J; Ndiaye K
    Emerg Infect Dis; 2018 Jan; 24(1):65-74. PubMed ID: 29260690
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Response to a Large Polio Outbreak in a Setting of Conflict - Middle East, 2013-2015.
    Mbaeyi C; Ryan MJ; Smith P; Mahamud A; Farag N; Haithami S; Sharaf M; Jorba JC; Ehrhardt D
    MMWR Morb Mortal Wkly Rep; 2017 Mar; 66(8):227-231. PubMed ID: 28253229
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Decision analysis in planning for a polio outbreak in the United States.
    Jenkins PC; Modlin JF
    Pediatrics; 2006 Aug; 118(2):611-8. PubMed ID: 16882814
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Population Immunity against Serotype-2 Poliomyelitis Leading up to the Global Withdrawal of the Oral Poliovirus Vaccine: Spatio-temporal Modelling of Surveillance Data.
    Pons-Salort M; Molodecky NA; O'Reilly KM; Wadood MZ; Safdar RM; Etsano A; Vaz RG; Jafari H; Grassly NC; Blake IM
    PLoS Med; 2016 Oct; 13(10):e1002140. PubMed ID: 27701425
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Effective partnership and in-country resource mobilization in Sudan for cVDPV2 outbreak response amid multiple emergencies in 2020-2021.
    Mashal MT; Eltayeb D; Higgins-Steele A; El Sheikh IS; Abid NS; Shukla H; Machado L; Jafari H
    BMC Public Health; 2024 Jan; 24(1):235. PubMed ID: 38243167
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Introduction of inactivated poliovirus vaccine leading into the polio eradication endgame strategic plan; Hangzhou, China, 2010-2014.
    Liu Y; Wang J; Liu S; Du J; Wang L; Gu W; Xu Y; Zuo S; Xu E; An Z
    Vaccine; 2017 Mar; 35(9):1281-1286. PubMed ID: 28161421
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Sabin Vaccine Reversion in the Field: a Comprehensive Analysis of Sabin-Like Poliovirus Isolates in Nigeria.
    Famulare M; Chang S; Iber J; Zhao K; Adeniji JA; Bukbuk D; Baba M; Behrend M; Burns CC; Oberste MS
    J Virol; 2016 Jan; 90(1):317-31. PubMed ID: 26468545
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Response to back-to-back outbreaks of circulating vaccine-derived poliovirus type 2 in two nomadic pastoralist settlements in Oti Region, Ghana-2019.
    Ameme DK; Yeboah YO; Odoom JK; Djokoto SK; Akyereko E; Mamudu A; Diwura M; Opare W; Avevor P; Diamenu S; Ohene SA; Kenu E; Asiedu-Bekoe F
    Arch Public Health; 2023 Jan; 81(1):1. PubMed ID: 36600260
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Progress toward poliomyelitis eradication--Nigeria, January 2013-September 2014.
    Etsano A; Gunnala R; Shuaib F; Damisa E; Mkanda P; Banda R; Korir C; Enemaku O; Corkum M; Usman S; Davis LB; Nganda Gw; Burns CC; Mahoney F; Vertefeuille JF;
    MMWR Morb Mortal Wkly Rep; 2014 Nov; 63(46):1059-63. PubMed ID: 25412063
    [TBL] [Abstract][Full Text] [Related]  

  • 59. The impact of surveillance and other factors on detection of emergent and circulating vaccine derived polioviruses.
    Auzenbergs M; Fountain H; Macklin G; Lyons H; O'Reilly KM
    Gates Open Res; 2021; 5():94. PubMed ID: 35299831
    [No Abstract]   [Full Text] [Related]  

  • 60. Implications of a circulating vaccine-derived poliovirus in Nigeria.
    Jenkins HE; Aylward RB; Gasasira A; Donnelly CA; Mwanza M; Corander J; Garnier S; Chauvin C; Abanida E; Pate MA; Adu F; Baba M; Grassly NC
    N Engl J Med; 2010 Jun; 362(25):2360-9. PubMed ID: 20573924
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.